Search

Author/Creator LaPlant, Betsy R.

2. Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia. Issue 4 (3rd April 2018)

Authors:
Kay, Neil E.; LaPlant, Betsy R.; Pettinger, Adam M.; Call, Timothy G.; Leis, Jose F.; Ding, Wei; Parikh, Sameer A.; Conte, Michael J.; Bowen, Deborah A.; Shanafelt, Tait D.
Journal:
Expert review of hematology
Issue:
Volume 11:Issue 4(2018)
Page Start:
337
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Detection of extranodal and spleen involvement by FDG‐PET imaging predicts adverse survival in untreated follicular lymphoma. Issue 7 (16th May 2019)

Authors:
St‐Pierre, Frédérique; Broski, Stephen M.; LaPlant, Betsy R.; Ristow, Kay; Maurer, Matthew J.; Macon, William R.; Habermann, Thomas M.; Ansell, Stephen M.; Thompson, Carrie A.; Micallef, Ivana N. M.; Nowakowski, Grzegorz S.; Witzig, Thomas E.
Journal:
American journal of hematology
Issue:
Volume 94:Issue 7(2019:Jul.)
Page Start:
786
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. Issue 8 (3rd August 2015)

Authors:
Zent, Clive S.; Call, Timothy G.; Bowen, Deborah A.; Conte, Michael J.; LaPlant, Betsy R.; Witzig, Thomas E.; Ansell, Stephen M.; Weiner, George J.
Journal:
Leukemia & lymphoma
Issue:
Volume 56:Issue 8(2015:Aug.)
Page Start:
2373
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. Issue 5 (10th March 2017)

Authors:
Bennani, N. Nora; LaPlant, Betsy R.; Ansell, Stephen M.; Habermann, Thomas. M.; Inwards, David J.; Micallef, Ivana N.; Johnston, Patrick B.; Porrata, Luis F.; Colgan, Joseph P.; Markovic, Svetomir N.; Nowakowski, Grzegorz S.; Macon, William R.; Reeder, Craig B.; Mikhael, Joseph R.; Northfelt, Don...
Journal:
American journal of hematology
Issue:
Volume 92:Issue 5(2017:May)
Page Start:
448
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Elevated soluble IL‐2Rα, IL‐8, and MIP‐1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. Issue 12 (19th September 2014)

Authors:
Sonbol, Mohamad B.; Maurer, Matthew J.; Stenson, Mary J.; Allmer, Cristine; LaPlant, Betsy R.; Weiner, George J.; Macon, William R.; Cerhan, James R.; Witzig, Thomas E.; Gupta, Mamta
Journal:
American journal of hematology
Issue:
Volume 89:Issue 12(2014:Dec.)
Page Start:
E223
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Fluorodeoxyglucose‐Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. (28th April 2020)

Authors:
St‐Pierre, Frédérique; Broski, Stephen M.; LaPlant, Betsy R.; Maurer, Matthew J.; Ristow, Kay; Thanarajasingam, Gita; Macon, William R.; Habermann, Thomas M.; Witzig, Thomas E.
Journal:
Oncologist
Issue:
Volume 25:Number 8(2020)
Page Start:
689
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results. Issue 4 (8th May 2022)

Authors:
Ailawadhi, Sikander; Parrondo, Ricardo D.; Moustafa, Muhamad Alhaj; LaPlant, Betsy R.; Alegria, Victoria; Chapin, Dustin; Roy, Vivek; Sher, Taimur; Paulus, Aneel; Chanan‐Khan, Asher A.
Journal:
Hematological oncology
Issue:
Volume 40:Issue 4(2022)
Page Start:
695
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. Issue 15 (20th May 2021)

Authors:
Khurana, Arushi; Mwangi, Raphael; Nowakowski, Grzegorz S.; Habermann, Thomas M.; Ansell, Stephen M.; LaPlant, Betsy R.; Link, Brian K.; Cerhan, James R.; Maurer, Matthew J.; Witzig, Thomas E.
Journal:
Journal of clinical oncology
Issue:
Volume 39:Issue 15(2021)
Page Start:
1641
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Long‐term follow‐up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B–cell non‐Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). Issue 10 (17th August 2017)

Authors:
Witzig, Thomas E.; Johnston, Patrick B.; LaPlant, Betsy R.; Kurtin, Paul J.; Pederson, Levi D.; Moore Jr, Dennis F.; Nabbout, Nassim H.; Nikcevich, Daniel A.; Rowland, Kendrith M.; Grothey, Axel
Journal:
American journal of hematology
Issue:
Volume 92:Issue 10(2017:Oct.)
Page Start:
1004
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗